about   CII home   shop   checkout

Accelerate Your Antibody Discovery with High-Throughput Kinetic Screening of Phage Libraries



November 9, 2017
11 am to 12 pm EST

 

Sponsored by
Carterra Logo

Preview:

 

Webinar Description:

Distributed Bio's phage display library has been computationally optimized based on the analysis of thousands of human antibody repertoires. Their library routinely produces over 5000 unique antibodies against any target.

How do they efficiently screen so many unique hits? They use the Carterra platform.

The Carterra LSA Array SPRi platform is the only antibody screening technology that can deliver high quality kinetic data directly from scFv bacterial supes at a high enough throughput to meet capacity, enabling thousands of clones to be screened in just days. This gives Distributed Bio the confidence to bypass ELISA screening and proceed directly to binding kinetics and epitope binning after panning. Combining Distributed Bio's phage display library with Carterra’s LSA, enables bioengineering feats that make many other discovery technologies obsolete and can help you achieve a one-week discovery cycle.

Learning Objectives:

  • Learn how Array SPRi accelerates kinetic screening of your antibody library by orders of magnitude
  • Survey the epitope landscape of your antibody library at the earliest stages of discovery
  • Identify unique epitopes while retaining epitope diversity
  • Build your IP portfolio

Speakers:

Jacob GlanvilleJacob Glanville, PhD

Co-Founder & Chief Science Officer

Distributed Bio


Jacob Glanville is the Co-Founder and Chief Science Officer of Distributed Bio, where he and his teams apply computationally-guided immunoengineering methods to enable a new generation of monoclonal antibody discovery and universal vaccine design. He has developed multiple seminal methods in the fields of high-throughput antibody repertoire sequencing (PNAS 2009), repertoire decoding algorithms (Nature 2017), single-cell TCR receptor & phenotype sequencing (Nature Biotech, 2014), deconstructing genetic variation in the adaptive immune system (Nature Communications 2015, Nature Reports 2016, PNAS 2011, TI 2017), and computationally guided antibody library engineering (JMB 2011, JMB 2013, COSB 2015). He is a Stanford University Scientific Advisory Committee member for the Sean Parker Center for Allergy and Asthma Research, a Scientific Advisory Board member for the University of San Francisco’s Biotechnology program, a repeat Gates Foundation/Stanford University Computational and Systems Immunology Grant Recipient while a PhD Candidate with Mark Davis at Stanford, a Recipient of Pfizer Achievement award 2010 while Principal Scientist at Pfizer, and has been a course-founding instructor and guest lecturer for multiple graduate-level applied computational and systems immunology courses at Stanford and USF.

Yasmina Noubia AbdicheYasmina Noubia Abdiche, PhD

Chief Science Officer

Carterra


Dr. Abdiche joined Carterra as CSO in 2016 after twelve and half years’ experience in the pharmaceutical industry at Rinat-Pfizer, where she was a Research Fellow, a member of Rinat’s leadership team, served on the governing committee for Pfizer’s Postdoctoral Program, and led a group of analytical scientists that applied label-free biosensors to the discovery of therapeutic antibodies. After graduating from Oxford University in the UK with a PhD in Biological Chemistry and a Master’s degree in Chemistry, Dr. Abdiche completed postdoctoral research in Dr. David Myszka’s laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions. Dr. Abdiche is co-inventor of several therapeutic antibodies in clinical trials, including Teva’s fremanezumab (formerly TEV-48125, RN-307) an anti-CGRP antibody which successfully completed PhIII clinical trials for chronic migraine and is expected to achieve US market approval in 2018, bococizumab, a PCSK9 inhibitor that was tested in PhIII clinical trials for hypercholesteremia, and RN888, a PD-1 inhibitor currently in PhI clinical trials for cancer immunotherapy.



Download Webinar